Featured Research

from universities, journals, and other organizations

Flu Vaccination Rates Lag For At-risk Adolescents

Date:
November 6, 2008
Source:
Harvard Medical School
Summary:
Influenza vaccination rates are still far too low for adolescents who suffer from asthma and other illnesses that predispose them to complications from the flu.

Influenza vaccination rates for adolescents who suffer from asthma and other illnesses are still far too low, according to a recent study.

The research, published in Pediatrics, was based at the Department of Ambulatory Care and Prevention at Harvard Medical School and Harvard Pilgrim Health Care.

"Influenza vaccination has been recommended for adolescents with high-risk conditions for well over a decade," notes lead author Mari Nakamura, a clinical fellow in pediatrics at Children's Hospital Boston. "We wanted to examine how effective this risk-based policy has been in achieving vaccination coverage."

Each year, between 20 and 40 percent of children and adolescents come down with the flu. For children with certain high-risk conditions, this can lead to severe illness, hospitalizations, and in some cases, even death. Because of this, the Centers for Disease Control strongly recommends that all adolescents vulnerable to influenza complications get vaccinated.

The study charted vaccination rates from 1992 to 2002 for 18,703 adolescents with asthma, cardiac disease, immune system disorders and other high-risk conditions who received care at Harvard Vanguard Medical Associates and were insured through Harvard Pilgrim Health Care. The investigators also identified medical visits for checkups and other preventive care that these adolescents had during flu seasons to determine whether there were missed opportunities for vaccination.

Vaccination rates improved during the study period, but only from 8 percent to 15 percent. During the last four years of the study period, 1999 to 2002, only 11 percent of adolescents with high-risk conditions received vaccinations during all four seasons. Over 56 percent of adolescents received no flu vaccinations during this four-year period.

Missed opportunities were common as approximately 45 to 55 percent of high-risk adolescents had one or more health care visits during the flu season at which the vaccine was not administered. In contrast, those who had preventive care visits were more likely to receive influenza vaccine.

Grace Lee of the Department of Ambulatory Care and Prevention, and senior author on the current study, published another study in the October issue of Pediatrics. In that study she found that among adolescents who had not been vaccinated for tetanus-diphtheria (Td), 75 percent did not receive an immunization despite visiting a healthcare provider.

Since 2005, three additional vaccines to prevent meningococcal disease, pertussis, and human papillomavirus have been approved and recommended for adolescents in the US. The introduction of these new vaccines has generated interest in improving how we track adolescent vaccinations.

The study team concludes both patients and providers need to be part of any intervention strategy aimed at increasing vaccination rates among this population. Previous research has also shown that letters to parents and electronic reminders for providers can be effective at improving vaccination rates.

The new recommendation for universal influenza vaccination of children and adolescents, issued by the CDC's Advisory Committee on Immunization Practices this past spring, may help to assure that adolescents are protected against the disease.

Dr. Nakamura observes, "Our findings lend support for the simplicity of universal vaccination. More adolescents, especially those with high-risk conditions, may be vaccinated if providers and parents don't first have to identify who meets criteria for vaccination, as under a risk-based approach."


Story Source:

The above story is based on materials provided by Harvard Medical School. Note: Materials may be edited for content and length.


Journal Reference:

  1. Nakamura et al. Influenza Vaccination in Adolescents With High-Risk Conditions. Pediatrics, 2008; 122 (5): 920 DOI: 10.1542/peds.2007-3032

Cite This Page:

Harvard Medical School. "Flu Vaccination Rates Lag For At-risk Adolescents." ScienceDaily. ScienceDaily, 6 November 2008. <www.sciencedaily.com/releases/2008/11/081103084055.htm>.
Harvard Medical School. (2008, November 6). Flu Vaccination Rates Lag For At-risk Adolescents. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/11/081103084055.htm
Harvard Medical School. "Flu Vaccination Rates Lag For At-risk Adolescents." ScienceDaily. www.sciencedaily.com/releases/2008/11/081103084055.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins